

Recombinant Human IFNG Cat No:HR2R1516

For research use only

Overview

Quantity	1.0 ?g
Gene Symbol	IFNG
Gene ID	3458
Accession	P01579
Alternative Name	IFN-gamma, Immune interferon, IFNG, type II interferon, T cell interferon, MAF br/>Recombinant Human Interferon-Gamma (IFNG)
Species	Human
Source	E. coli IFN-gamma is produced mainly by T cells and natural killer cells activated by antigens, mitogens, or alloantigens. It is produced by lymphocytes expressing the surface antigens CD4 and CD8. IFN gamma receptors are expressed on all types of human cells with the exception of mature erythrocytes. IFN-gamma-receptor complexes are rapidly internalized by endocytosis. IFN-gamma has antiviral and antiparasitic activities and also inhibits the proliferation of a number of normal and transformed cells. Interferon-gamma synergises with TNF-alpha and TNF- beta in inhibiting the proliferation of various cell types. The growth inhibitory activities of IFN-gamma are more pronounced than those of the other interferons. However, the main biological activity of IFN-gamma appears to be
Functions	immunomodulatory in contrast to the other interferons that are mainly antiviral. T-helper cells and IL-2 induces the synthesis of IFN-gamma and other cytokines. IFN- gamma acts synergistically with IL-1 and IL-2 and appears to be required for the expression of IL-2 receptors on the cell surface of T-lymphocytes. Blocking of the IL-2 receptor by specific antibodies also inhibits the synthesis of IFN-gamma. The ED(50) was determined by a viral resistance assay of mouse L929 cells and was found to be ? 1.0 ng/mL, corresponding to a specific activity of ? 1.0 x 10^6 units/mg.
Formulation	Recombinant Interferon gamma was lyophilized from a 0.2 ?m filtered concentrated (1.0 mg/mL) solution in PBS, pH 7.2.
Solubility	A quick spin of the vial followed by reconstitution in distilled water to a concentration not less than 0.1 mg/mL. This solution can then be diluted into other buffers.
Appearance	Lyophilized Powder
Molecular Weight	17
Purity	>95% as determined by SDS-PAGE
Concentration	<1.0 EU/?g of recombinant protein as determined by the LAL method.
Shipping Condition	Ambient Temperature
	www.bioelsa.com info@bioelsa.c

Storage Condition	Storago	The lyophilized protein is stable for at least one year from date of receipt at -70?C. Upon reconstitution, this
	cytokine can be stored in working aliquots at 2? - 8?C for one month, or at -20?C for six months, with a carr	
	Condition	protein without detectable loss of activity. Avoid repeated freeze/thaw cycles.



or at -20?C for six months, with a carrier